Wikipedia -WSS

Wikipedia

author：explore 2025-09-02 08:10:11 - browse：45257

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Complete sequence of Y chromosome published for first time

focus

WSS

Kaiser's Risant Health gobbled up Geisinger. Who is next?

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

AstraZeneca challenges Medicare drug negotiation program

See how much Covid

Cord blood banking comes at a high cost to babies

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

entertainment

Wikipedia

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

Neuroscience startup Neumora files for IPO

BioMarin wins approval for gene therapy to treat hemophilia A

Apellis safety probe of eye disease drug centers on injection needle

Moonlake's readout produced a cash windfall. Risks remain

NYU Langone launches private ChatGPT for its health care data

FDA approval of Sarepta Duchenne genetic therapy gives me hope

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Virginia high school admissions case could be legal follow

Shifting the focus from loneliness to social health

entertainment

Letters to First Opinion on caregivers, digital health, and more

Let's speed up science by embracing open access publishing

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Let's speed up science by embracing open access publishing

Cord blood banking comes at a high cost to babies

AstraZeneca bets AAV gene therapy will still deliver the goods

hotspot

focus

focus

knowledge